The Sotex company took part in the V All-Russian “Russia – concerns of the territory”
Sotex took part in the V All-Russian “Russia – Territories of Care”, which took place on November 2-3 in an online format. The event was organized with the participation of the Ministry of Health of the Russian Federation, the Ministry of Labor, the Russian National Research Medical University. N.I. Pirogov, the Russian Scientific and Clinical Gerontological Center, the Russian Association of Gerontologists and Geriatricians and with the support of the Federation Council. More than 3,500 doctors, nurses and social workers from all over Russia took part in it.
The main topic of the forum was the idea of creating a society in which people do not worry about aging. During the symposiums and discussions, various aspects of this issue were imbued: medical, social, economic. In this aspect, the prevention of age-associated diseases and geriatric syndromes, in particular joint diseases, is of particular importance. In maintaining the health of the joints, the drug company “Sotex” based on chondroitin sulfate can help. The possibilities of its use in osteoarthritis and joint pain were the subject of two reports presented during the forum.
Chief freelance specialist-geriatrician of the Ministry of Health of Russia, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences Olga Tkachev in anticipation of “The onset of the development of the musculoskeletal system and osteoarthritis: problems of rapid state and” success prospects are marked by the treatment with parenteral chondroitin sulfate in patients with articular syndrome after a coronavirus infection. Relevant research results were carried outone on the fact of the incident ESCEO2 in Berlin in 2022, and also published in Modern Rheumatology (2022)3.
Also, Professor Olga Tkacheva focused on the importance of having affordable treatment for diseases in patients and announced the imminent appearance on the market of a promising chondroprotector from Sotex with native type II collagen.
In turn, behind the laboratory of age-related metabolic and endocrine associations of the RGNCC of the Ministry of Health of the leading Russia, MD. Catherine Dudinskaya In the report “Modern advances in the diagnosis and therapy of the metabolic phenotype of osteoarthritis: focus on the metabolic syndrome and thyroid dysfunction” the practitioner spoke about the main diseases of osteoarthritis in patients with metabolic diseases and conditions accompanied by impaired carbohydrate detection and impaired thyroid function. She noted that parenteral chondroitin sulfate has a solid evidence base and approval in four notable recommendations of the Russian Ministry of Health.4-7. This fact is a preliminary examination when choosing the tactics of treating patients with osteoarthritis and associated endocrinological pathology, added by a specialist.
Carrying out such events is extremely important for conducting experiments on the work of specialists for various purposes and identifying organizations of medical care for patients of elderly and senile age, as well as the emergence of conditions for their use of longevity, the emergence in the Sotex company.
one ESCEO – European Society for the Clinical and Economics of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, European Society for the Development and Economics of Osteoporosis and Osteoarthritis.
2 https://virtual.wco-iof-esceo.org/sites/wco_22/pdf/WCO22-AbstractBook.pdf p.362, p.520.
3 Sarvilina I.V., Dydykina I.S., Lila A.M. Modern possibilities of pharmacological correction of neuroimmune joint damage in patients with osteoarthritis of the knee joint in conditions of long-term COVID // Modern Rheumatology. 2022;16(3):67–74. DOI: 10.14412/1996-7012-2022-3-67-74.
four https://cr.minzdrav.gov.ru/recomend/667_1.
5 https://cr.minzdrav.gov.ru/recomend/666_1.
6 https://cr.minzdrav.gov.ru/recomend/616_1.
7 https://cr.minzdrav.gov.ru/recomend/600_2.
Partner material: “Sotex”